SEC Form 4
Aardvark Therapeutics, Inc. (AARD) insider trading
In the 12 months to Oct 26, 2026, one AARD insider reported open-market sales of $395.0K across 1 filing; 2 insiders bought $144.6K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $395.0K
- 1 filing · 1 insider
- Open-market purchases
- $144.6K
- 2 filings
- Pre-arranged sales (10b5-1)
- 1 of 1
- All $395.0K sold was pre-arranged
Who traded AARD, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
AARD daily close from Oct 27, 2025 to Oct 26, 2026, between $1.08 and $15.82, last $1.08. 1 sale and 2 purchase filings by 2 insiders, marked at their filing dates. Nelson Sun, Chief Financial Officer → Officer (see filing): sold $395.0K and bought $43.2K across 2 filings, first filed Dec 12, 2025, last Sep 11, 2026. Tien-Li Lee, Chief Executive Officer: bought $101.4K across 1 filing, first filed Dec 12, 2025, last Dec 12, 2025.
Largest mark · tap a row for others
Nelson Sun · Officer (see filing)
Sale $394,957
76,754 shares at $5.15 avg
Filed Sep 11, 2026 · traded Sep 10
Pre-arranged (10b5-1) · close on filing date $5.13
Nelson Sun · Chief Financial Officer → Officer (see filing)
Chief Financial Officer → Officer (see filing)
$395.0K sold$43.2K boughtTien-Li Lee · Chief Executive Officer
Chief Executive Officer
$101.4K boughtOpen-market trades
3 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Nelson Sun | Chief Financial Officer → Officer (see filing) | $395.0K | $43.2K | 2 | 100% of sales | |
| Tien-Li Lee | Chief Executive Officer | — | $101.4K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Nelson Sun Officer (see filing) | SalePre-arranged (10b5-1) | 76,754 | $5.15 | $395.0K | 35,475 | |
traded | Tien-Li Lee Chief Executive Officer | Purchase | 7,000 | $14.49 | $101.4K | 1,551,613 | |
traded | Nelson Sun Chief Financial Officer | Purchase | 3,000 | $14.40 | $43.2K | 108,484 |
GET /stocks/filings/vX/form-4?tickers=AARD&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AARD"
],
"issuer_cik": "0001774857",
"owner_cik": "0002045377",
"accession_number": "0001193125-26-389564",
"form_type": "4",
"filing_date": "2026-09-11",
"period_of_report": "2026-09-10",
"issuer_name": "Aardvark Therapeutics, Inc.",
"issuer_trading_symbol": "AARD",
"owner_name": "Sun Nelson",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "See Remarks",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock, par value $0.00001 per share",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-10",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 14754,
"transaction_price_per_share": 5.0006,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 97475,
"transaction_value": 73778.8524,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."
},
{
"id": "F3",
"description": "Includes 3,745 shares of common stock acquired pursuant to the Issuer's 2025 Employee Stock Purchase Plan on May 22, 2026."
}
],
"remarks": "Chief Financial & Operating Officer"
},
{
"tickers": [
"AARD"
],
"issuer_cik": "0001774857",
"owner_cik": "0002045377",
"accession_number": "0001193125-26-389564",
"form_type": "4",
"filing_date": "2026-09-11",
"period_of_report": "2026-09-10",
"issuer_name": "Aardvark Therapeutics, Inc.",
"issuer_trading_symbol": "AARD",
"owner_name": "Sun Nelson",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "See Remarks",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock, par value $0.00001 per share",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-11",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 62000,
"transaction_price_per_share": 5.1803,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 35475,
"transaction_value": 321178.6,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026."
}
],
"remarks": "Chief Financial & Operating Officer"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Aardvark Therapeutics, Inc.'s CEO sold stock?
No. Tien-Li Lee (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is AARD’s insider data?
These are AARD Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AARD insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AARD every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.